Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 16, 2013

View Archived Issues

Nintedanib shows no activity against recurrent high-grade gliomas

Phase II trial planned after phase I study completed with selumetinib in children with gliomas

Bispecific hexavalent antibody shows promise for treating lupus

ImmunoCellular Therapeutics reports phase II data for ICT-107

Integral Molecular generates MAbs against the P2X3 ion channel

KaloBios Pharmaceuticals presents phase I results for KB-004

AGI-14100 significantly reduces tumor burden in IDH1-mutant mouse model

Swiss group discloses new MPC modulators

Convergence Pharmaceuticals prepares novel sodium channel blockers for pain

New potassium channel modulators patented by Autifony Therapeutics

Piramal Enterprises synthesizes new pyrimidine compounds

Korean researchers present new antibodies that bind to RANKL for bone disorders

Mallinckrodt completes clinical trials of MNK-155

Novel Trk-A inhibitors designed by Merck & Co.

SPX-106T lowers cholesterol and triglyceride levels and prevents weight gain in vivo

Canadian approval for Lemtrada

FDA advisory committee votes in favor of Oralair for grass pollen allergy

Stem cell candidate receives orphan drug designation in Japan

FDA advisory committee recommends approval of dapagliflozin

Celator's phase III study of CPX-351 for AML cleared to continue by DSMB

CDRD Ventures launches spin-off company Kairos Therapeutics

Dementia Consortium launched in the UK to advance drug development

FDA approves Complera for patients with HIV switching from a stable regimen

Endocyte begins phase I study of EC-1456 in advanced solid tumors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...